Nexus rendering

This rendering depicts Nexus Pharmaceuticals’ planned manufacturing facility, to be built in Pleasant Prairie.

PLEASANT PRAIRIE — A village panel approved plans for two pharmaceutical companies — one that processes medication for critically ill patients, the other which manufactures specialty and generic drugs.

The Plan Commission voted unanimously Monday night on final site and operational plans for Fresenius Kabi, which is establishing a regional office, pharmaceutical warehouse and processing facility at 11900 122nd St. in the Stateline 94 Corporate Park.

In late June, the commission approved the conditional use permit for the 590,595-square-foot center located on a 46.9-acre parcel site which is being developed by Venture One Real Estate and CRG.

Fresenius Kabi, with U.S. headquarters in Lake Zurich, Ill., specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to care for critically and chronically ill patients.

The facility is expected to begin operations next year. It is expected to employ 95 workers on two shifts within the first three years with as many 164 employees by 2028.


The commission also unanimously approved the preliminary site and operational plans for Nexus Pharmaceuticals Inc. for site grading, underground utilities, and footing and foundation for a proposed 100,000-square-foot manufacturing facility at the northwest quadrant of Highway Q and 128th Avenue in Prairie Highlands Corporate Park.

Last month, Nexus entered into an agreement to purchase 16 acres in the corporate park for $3.2 million from the village. The Village Board unanimously approved the agreement.

Nexus specializes in developing innovative processes to manufacture specialty and generic injectable drugs for a variety of therapeutic areas including anesthesia, oncology, cardiovascular and neurology.

Headquartered in Lincolnshire, Ill., the proposed facility for the village is an expansion of its business.

Three phases

Nexus’ three-phase, multi-year project is expected to be completed in 10 years.

The first phase will involve the construction of the $85 million, three-story manufacturing facility. The facility will house cutting-edge technology, including an advanced isolator system for maximum product protection and sterility, reducing the risk of contamination.

Additional land to the west of first building would enable potential growth of $250 million with future expansion.

Waste concerns

Commission Chairman Michael Serpe questioned Nexus about the safeguards in place during the manufacturing process to prevent chemicals from entering sewer systems.

John Cook, Nexus’ vice president of manufacturing operations, said most of the materials would be disposable, and any residual product would go to into a container that would then be taken by waste services.

“So that would never enter the waste stream,” he said.

He added that materials used during the cleaning process would go into a “neutralization tank.”

He said the company contracts for manufacturing but in his 30 years of experience there have been no incidents that have led to such materials entering sewer systems.

He said a response team would notify the village if such an incident occurred.

The facility will also include multiple freeze-drying machines to support production of the company’s current portfolio of generic and specialty injectable drugs.

77 new jobs

The construction’s first phase is expected to be completed in 2021 with commercial production to start in 2022.

Nexus expects to create 77 new jobs, with an average salary of about $70,000 annually, according to the plans.

Commissioner Michael Pollocoff asked whether employees were being relocated to the proposed facility.

“These will all be new employees,” Cook said.